Top Ten most popular articles on this week

pharmafile | February 14, 2020 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing China, Chinese Coronavirus, Wuhan, Wuhan Coronavirus, china coronavirus, coronavirus 

The coronavirus continues to dominate the news, with the disease finally getting treated. In America, a patient has been successfully treated with an Ebola drug from Gilead. This drug is also being used in China on patients with mass production set to start soon.

Pharmaceutical companies have also seen some staff shakeups, with GlaxoSmithKline set to cut 720 jobs in Belgium while Sanofi has axed five members of its executive committee.

10. Highest fatalities from coronavirus recorded in a single day due to new classifications

The coronavirus outbreak reached its deadliest day since it began in December.

9. NICE plans to use broader range of data in guidance

The British National Institute for Care Excellence has said it plans to use a broader range of data and analytics in its guidance. This will include real-world evidence and electronic health records.

8. Eli Lilly’s solanezumab fails at Phase 2/3 in early-onset Alzheimer’s disease

In another blow to Alzheimer’s research, it has emerged that a study investigating Eli Lilly’s solanezumab in the treatment of early-onset Alzheimer’s disease failed to meet its primary endpoint.

7. Several European cases of coronavirus traced to ski resort in the Alps

Multiple European cases of coronavirus have been traced to a ski resort in the Alps, with a British man spread the disease to several others he came into contact with.

6. Roche’s experimental Alzheimer’s drug does not meet primary endpoint in clinical trials

Roche has said its experimental drug, gantenerumab, did not meet its primary endpoint in people who have an inherited form of Alzheimer’s disease.

5. Sanofi axes four major players from its executive committee

Sanofi has announced it will cull its executive committee under plans orchestrated by new Chief Executive Officer Paul Hudson, who joined the company in September last year.

4. 85% of patients see benefit in clinical trials, but 43% were never given the option to participate, report finds

Patients regularly find value in participating in clinical trials, but many are not given the option by medical professionals and some were outwardly discouraged form taking part, says a new report from Patient Power, a media organisation providing “patient-powered journalism, information and opportunities.”

3. GSK to axe 720 positions at Belgian vaccine facility

GlaxoSmithKline has announced a cull of staff at its vaccine production site in Belgium, with 720 employees facing the axe.

2. Patient successfully treated for coronavirus in the US

Health officials in the US say they have successfully treated a man for coronavirus with an experimental drug.

1. Chinese company starts mass producing Gilead coronavirus drug

A drugmaker in China said it has started mass producing Gilead Sciences Ebola drug that has the potential to fight the coronavirus.

Related Content

China rejects a second WHO probe into COVID outbreak origin

China has rejected WHO plans for a second investigation into the origin of the coronavirus …

Positive phase III results achieved for dialysis drug in China

Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced positive results from a phase-III study …

coronavirus’s weekly COVID-19 news round-up

The past week has continued to see positive COVID-19 news; CytoDyn’s treatment for patients with …

Latest content